Syddansk Universitet

EAACI Guidelines on Allergen Immunotherapy

Prevention of allergy

Halken, Susanne; Larenas-Linnemann, Desiree; Roberts, Graham; Calderón, Moises A; Angier, Elisabeth; Pfaar, Oliver; Ryan, Dermot D; Agache, Ioana; Ansotegui, Ignacio J I J; Arasi, Stefania; Du Toit, George; Fernandez-Rivas, Montserrat; Geerth van Wijk, Roy; Jutel, Marek; Kleine-Tebbe, Jörg; Lau, Susanne; Matricardi, Paolo M; Pajno, Giovanni B; Papadopoulos, Nikolaos G; Penagos, Martin; Santos, Alexandra F; Sturm, Gunter J; Timmermans, Frans; Van Ree, R; Varga, Eva-Maria; Wahn, Ulrich; Kristiansen, Maria; Dhami, Sangeeta; Sheikh, Aziz; Antonella, Muraro

Published in:
Pediatric Allergy and Immunology

DOI:
10.1111/pai.12807

Publication date:
2017

Document version
Peer reviewed version

Document license
CC BY-NC

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 09. jan., 2019
EAACI Guidelines on Allergen Immunotherapy: Prevention of allergy

Susanne Halken¹, Desiree Larenas-Linnemann², Graham Roberts³, Moises A Calderón⁴, Elisabeth Angier⁵, Oliver Pfaar⁶,⁷, Dermot Ryan D⁸, Ioana Agache⁹, Ignacio J Ansotegui IJ¹⁰, Stefania Arasi¹¹,¹², George Du Toit¹³, Montserrat Fernandez-Rivas¹⁴, Roy Geerth van Wijk¹⁵, Marek Jutel¹⁶,¹⁷, Jörg Kleine-Tebbe¹⁸, Susanne Lau¹², Paolo M Matricardi¹², Giovanni B Pajno¹¹, Nikolaos G Papadopoulos¹⁹,²⁰, Martin Penagos⁴, Alexandra F Santos¹⁵, Gunter J Sturm²¹, Frans Timmermans²², van Ree R²³, Eva-Maria Varga²⁴, Ulrich Wahn⁹, Maria Kristiansen²⁵, Sangeeta Dhami²⁶, Aziz Sheikh²⁰, Antonella Muraro²⁷

Affiliations:

Halken S: 1) Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark;

Larenas-Linnemann D: 2) Investigational Unit, Hospital Medica Sur, Mexico City, Mexico;

Roberts G: 3) The David Hide Asthma and Allergy Research Centre, St Mary's Hospital, Newport Isle of Wight, UK, NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK, and Faculty of Medicine, University of Southampton, Southampton, UK;

Calderón MA: 4) Section of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Royal Brompton Hospital, London United Kingdom;

Angier E: 5) Department of Immunology and Allergy, Northern General Hospital, Sheffield, UK

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/pai.12807

This article is protected by copyright. All rights reserved.
Pfaar O: 6) Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 7) Center for Rhinology and Allergology, Wiesbaden, Germany;

Ryan D: 8) Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK; Asthma UK Centre for Applied Research, The University of Edinburgh, Edinburgh, UK;

Agache I: 9) Transylvania University Brasov, Faculty of Medicine, Department of Allergy and Clinical Immunology, Brasov, Romania.

Ansotegui IJ: 10) Department of Allergy & Immunology Hospital Quironsalud Bizkaia, Erandio – Bilbao, Spain;

Arasi S: 11) Department of Pediatrics, Allergy Unit, University of Messina, Italy; 12) Department for Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany;

Du Toit G: 13) Department of Paediatric Allergy, MRC & Asthma Centre in Allergic Mechanisms of Asthma, Division of Asthma, Allergy and Lung Biology, King’s College London and Guy’s & St Thomas’ Hospital NHS Foundation trust, London, United Kingdom;

Fernandez-Rivas M: 14) Allergy Department, Hospital Clinico San Carlos, IdiSSC, Madrid, Spain

Geerth van Wijk R: 15) Section of Allergology, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands;

Jutel M: 16) Department of Clinical Immunology; Wroclaw Medical University, Poland, 17) ALL-MED Medical Research Institute

Kleine-Tebbe J: 18) Allergy & Asthma Center Westend, Berlin, Germany;

Lau S: 12) Department for Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany;

Matricardi PM: 12) Department for Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany;

Pajno GB: 11) Department of Pediatrics, Allergy Unit, University of Messina, Italy;

Papadopoulos NG: 19) Institute of Human Development, University of Manchester, UK; 20) Allergy Department, 2nd Pediatric Clinic, University of Athens, Greece

This article is protected by copyright. All rights reserved.
Penagos M: 4) Section of Allergy and Clinical Immunology, Imperial College London, National Heart and Lung Institute, Royal Brompton Hospital, London United Kingdom;

Santos AF: 13) Department of Paediatric Allergy, MRC & Asthma Centre in Allergic Mechanisms of Asthma, Division of Asthma, Allergy and Lung Biology, King’s College London and Guy’s & St Thomas’ Hospital NHS Foundation trust, London, United Kingdom;

Sturm GJ: 21) Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria;

Outpatient Allergy Clinic Reumannplaz, Vienna, Austria;

Timmermans F: 22) Nederlands Anafylaxis Netwerk - European Anaphylaxis Taskforce, Dordrecht, Netherlands;

van Ree R: 23) Departments of Experimental Immunology and of Otorhinolaryngology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands;

Varga E-M: 24) Department of Pediatric and Adolescent Medicine, Respiratory and Allergic Disease Division, Medical University of Graz, Graz, Austria;

Wahn U: 12) Department for Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany;

Kristiansen M: 25) Department of Public Health, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Dhami S: 26) Evidence Based Health Care Ltd, Edinburgh UK.

Sheik A 8) Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK; Asthma UK Centre for Applied Research, The University of Edinburgh, Edinburgh, UK;

Muraro A: 27) The Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region. Department of Women and Child Health – University of Padua. Padua, Italy;

External expert panel: Steven Durham, Peter Eng, Hans Jørgen Malling, Antonio Nieto, Zolt Szefalusi and Erkka Valovirta

Running title: EAACI Guideline: AIT for Allergy Prevention

This article is protected by copyright. All rights reserved.
Abstract

Allergic diseases are common and frequently coexist. Allergen immunotherapy (AIT) is a disease-modifying treatment for IgE-mediated allergic disease with effects beyond cessation of AIT that may include important preventive effects. The European Academy of Allergy and Clinical Immunology (EAACI) has developed a clinical practice guideline to provide evidence-based recommendations for AIT for prevention of i) development of allergic comorbidities in those with established allergic diseases, ii) development of first allergic condition and iii) allergic sensitization. This guideline has been developed using the Appraisal of Guidelines for Research & Evaluation (AGREE II) framework, which involved a multi-disciplinary expert working group, a systematic review of the underpinning evidence and external peer-review of draft recommendations. Our key recommendation is that a three year course of subcutaneous or sublingual AIT can be recommended for children and adolescents.
with moderate to severe allergic rhinitis (AR) triggered by grass/birch pollen allergy to prevent asthma for up to two years post-AIT in addition to its sustained effect on AR symptoms and medication. Some trial data even suggest a preventive effect on asthma symptoms and medication more than two years post AIT. We need more evidence concerning AIT for prevention in individuals with AR triggered by house dust mites or other allergens and for the prevention of allergic sensitization, the first allergic disease or for prevention of allergic co-morbidities in those with other allergic conditions. Evidence for the preventive potential of AIT as disease modifying treatment exists but there is an urgent need for more high-quality clinical trials.

**Keywords:** Allergen immunotherapy, allergic diseases, allergy, atopy, prevention, sensitization, AGREE II, asthma, allergic rhinitis; atopic dermatitis/eczema

**Author to whom requests for offprints should be sent:**
Antonella Muraro, Department of Women and Child Health, Referral Centre for Food Allergy Diagnosis and Treatment Veneto Region, - University of Padua, Via Giustiniani 3, 35128 Padua, Italy
Tel. +39 049 821 2538 - Fax +39 049 8218091 – Email muraro@centroallergialimentari.eu

**Abbreviations:**
AD:       Atopic dermatitis (atopic eczema)
AIT:      Allergen immunotherapy
AR:       Allergic rhinitis / Allergic rhinoconjunctivitis
ARIA:     Allergic Rhinitis and its Impact of Asthma
CBA:      Controlled before and after study
EMA:      European Medicines Agency
HDM:      House dust mite
OAS:      Oral allergy syndrome
Qol:      Quality of life
RCT:      Randomized controlled trial
SCIT:     Subcutaneous immunotherapy
SLIT:     Sublingual immunotherapy

This article is protected by copyright. All rights reserved.
**Introduction**

Allergic diseases are among the commonest chronic diseases and encompass atopic eczema/dermatitis (AD), asthma, allergic rhinitis and allergic rhinoconjunctivitis (both from here onward referred to as AR), food allergy and venom allergy [1-5]. They frequently start in early childhood and continue throughout adulthood. Allergies can cause a considerable burden to individuals leading to impaired quality of life [6]. At a societal level, they cause additional costs, particularly in terms of healthcare utilization, reduction in economic productivity and impacting on activities of daily living. The latter may include loss of school days, work absence, presenteeism and early retirement [7;8]. For allergic asthma and AR, many patients respond well to pharmacotherapy, whereas others do not or need treatment with more than one product [9]. However, there is good evidence for the clinical efficacy of allergen immunotherapy (AIT) for AR, allergic asthma and moderate to severe venom allergy [10-12] with many patients responding to therapeutic AIT, leading to a sustained reduction in symptoms and requirement for symptomatic treatment.

AIT is considered a disease-modifying intervention in IgE-mediated allergic disease, with both a therapeutic, even beyond cessation of AIT [10-12], and the potential for a preventive effect [13-16]. It has been shown that children with AR have a 3-fold increased risk of developing asthma [17;18] and that childhood AD and AR are strongly associated with the incidence and persistence of adult atopic asthma and with allergic asthma persisting into adulthood [19]. Studies assessing the long-term effectiveness of AIT in children with AR indicate that AIT might reduce the risk of developing asthma [20-23]. AIT has the potential to induce immunological changes that result in immune modification [14]. Therefore, AIT should be considered as a preventive strategy in the treatment of allergic diseases.

This Guideline has been developed by the European Academy of Allergy and Clinical Immunology (EAACI) Taskforce on AIT for Allergy Prevention and form part of the EAACI Guidelines on Allergen Immunotherapy. The aim is to provide evidence-based recommendations for the use of AIT for prevention of i) further allergic co-morbidities in those with established allergic disease, ii) first allergic
disease and iii) development of allergic sensitization. This Guideline does not cover prevention of symptoms, exacerbations or progression of already existing allergic disease since this is included in other guidelines in this series. Likewise it does not cover weaning and dietetic strategies, which are considered in the ‘EAACI food allergy and anaphylaxis guidelines: Primary prevention of food allergy’ [24]. Definition of key terms are described in Box 1.

The primary audience for this Guideline are clinical allergists (specialists and subspecialists). It may also provide guidance for other healthcare professionals e.g., physicians, nurses and pharmacists working across a range of primary, secondary and tertiary care settings managing patients with allergic diseases and healthy individuals at risk of developing allergic diseases.

<table>
<thead>
<tr>
<th>Box 1. Key terms</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Allergic asthma</strong></td>
</tr>
<tr>
<td><strong>Allergic conjunctivitis</strong></td>
</tr>
<tr>
<td><strong>Allergic diseases</strong></td>
</tr>
<tr>
<td><strong>Allergic rhinitis</strong></td>
</tr>
<tr>
<td><strong>AIT (Allergen immunotherapy)</strong></td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved.
- Subcutaneous immunotherapy (SCIT): Form of AIT where the allergen is administered as subcutaneous injections

- Sublingual immunotherapy (SLIT): Form of AIT where the allergen is administered under the tongue with formulation as drops or tablets

<table>
<thead>
<tr>
<th>Healthy individuals</th>
<th>Individuals with or without IgE sensitization, but without any manifestations of current allergic disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prevention</strong></td>
<td>Prevention of the development of a new sensitization or new allergic disease in healthy individuals without sensitizations, in healthy individuals with sensitizations and in those who already have an allergic disease</td>
</tr>
<tr>
<td></td>
<td><strong>Short-term prevention</strong>: preventive effect assessed within a two year window post-AIT</td>
</tr>
<tr>
<td></td>
<td><strong>Long-term prevention</strong>: preventive effect maintained after at least two years post-AIT</td>
</tr>
<tr>
<td></td>
<td>In this document, specific treatment effects such as effect on exacerbations and progression of the disease, including long-term effects, are not regarded as prevention.</td>
</tr>
</tbody>
</table>

| Sensitization       | Detectable specific IgE antibodies, either by means of SPT or determination of specific-IgE antibody levels in a serum sample |

*Dietary interventions in infants aimed at the prevention of food allergy* are not covered in this Guideline: they form part of the ‘EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy’ [24].

**Methods**

Development of the Guideline has been informed by a formal systematic review [25] and meta-analysis of AIT for prevention of allergy [25] with SR principles being used to identify additional evidence, where necessary.
This Guideline was produced using the Appraisal of Guidelines for Research & Evaluation (AGREE II) approach [26;27]. This structured method for guideline production is designed to ensure appropriate representation of the full range of stakeholders, an exhaustive search for and critical appraisal of the relevant literature, a systematic approach to the formulation and presentation of recommendations, and steps to ensure that the risk of bias is minimized at each step of the process. The process began in April 2015 with detailed face-to-face discussions agreeing on the process and the key clinical areas to address, followed by face-to-face and web-conferences in which professional and lay representatives participated.

Clarifying the scope and purpose of the guidelines

The scope of this EAACI Guideline is multifaceted, providing recommendations that assist clinicians in the optimal use of AIT for the prevention of development of allergic disease in the management of individuals with, or at risk for, allergic disease, and identifying gaps for further research. The Guideline builds on a SR conducted to summarise the evidence base in relation to these aims (Box 2) [25].

<table>
<thead>
<tr>
<th>Box 2: Summary of the aim and outcomes in the supporting systematic review [25]</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim:</strong> To provide the evidence basis for formulating clinical practice guidelines for the use of AIT as preventive therapeutic intervention in allergy. This will be based on a rigorous evaluation of current SR evidence on the effectiveness, safety and cost-effectiveness of AIT for prevention of allergic sensitization(s) and allergic disease(s).</td>
</tr>
</tbody>
</table>
| **Outcomes of the SR:**  
| **Primary**  
| The development of the first allergic manifestation in healthy individuals, or of a new allergic manifestation in those with a previous allergic condition (e.g. development of asthma in patients with atopic eczema/dermatitis (AD) or AR, assessed over the short term (< 2 years) or the longer term (≥ 2 years) post-AIT |
| **Secondary**  
| The development of new allergic sensitization(s), spreading of allergic sensitization(s) from one allergen to other non-related allergen(s), spreading of allergic sensitization(s) at molecular level, from one allergenic molecule to other molecules |
| The development of previously non-existent oral allergy syndrome (OAS)  
| Safety as assessed by local and systemic reactions in accordance with the World Allergy Organization’s (WAO) grading systems of local and systemic side-effects [28;29].  
| Health economic analysis from the perspective of the health system/payer as reported in studies |

Ensuring appropriate stakeholder involvement

Participants in the EAACI Taskforce on AIT for Prevention represented a range of countries, with various disciplinary and clinical backgrounds, including allergists, primary care physicians, allied health professionals, public health practitioners, representatives from patient interest organisations.
and methodologists who took the lead in undertaking the underpinning SR. Additionally, producers of immunotherapy products were given the opportunity to review and comment on the draft guidelines as part of the peer review and public comment process. The Taskforce members considered these comments and revised the Guideline, where appropriate.

**Systematic reviews of the evidence**

The initial full range of questions that were considered important were rationalized through several rounds of iteration to agree on one key overarching question: “What is the effectiveness, safety and cost-effectiveness of AIT for prevention of allergic disease and sensitization in all populations?”. This was then pursued through a formal SR of the evidence by independent methodologists as previously published [25;30]. We continued to track evidence published after our SR cut-off date October 31, 2015 and, where relevant, studies were considered by the Taskforce chairs and members.

**Formulating recommendations**

We graded the strength and consistency of key findings from the SR and meta-analysis, using a random-effects model to take into account the heterogeneity of findings [25] to formulate evidence-based recommendations for clinical care, using an approach that was adapted from that proposed by the Oxford Centre for Evidence-Based Medicine (Oxford Centre for Evidence-based Medicine) (Box 3) [31]. The adaptation involved providing an assessment of the risk of bias, based on the Cochrane risk of bias tool, of the underpinning evidence and highlighting other potentially relevant contextual information, formulating clear recommendations and making clear the evidence-base underpinning each recommendation. Where the systematic review did not cover the clinical area, we took a hierarchical approach reviewing other evidence until we could formulate a recommendation, i.e.: (i) other systematic reviews on the subject to see if these provided any clarity on the topic; (ii) RCTs within these systematic reviews; (iii) other RCTs known to Taskforce members; and (iv) a consensus-based approach within the Taskforce. This evidence was graded as described in Box 2 using the systematic review data and clearly labelled in the recommendation tables. In formulating the recommendations not only possible beneficial effects, but also any possible disadvantages and harms was considered (Table 1).
Identification of evidence gaps

The process of developing this Guideline has identified a number of evidence gaps, which are prioritized in Table 2.

Implementation of the Guideline

The Taskforce members identified the resource implications, barriers and facilitators to the implementation of each recommendation (Tables 3-5), advised on approaches to implementing the recommendations and suggested audit criteria that can help with assessing organizational compliance with each recommendation (Table 6).
Peer-review and public comment

A draft of this Guideline was externally peer-reviewed by invited external experts in this field from a range of organizations, countries and professional backgrounds: Stephen Durham, Peter Eng, Hans Jørgen Malling, Antonio Nieto, Zsolt Szepfalusi and Erkka Valovirta. Additionally, the draft Guideline were made available on the EAACI website for a three-week period in May 2017 for public review to allow a broader array of stakeholders to comment. All feedback was considered by the Taskforce members and, where appropriate, final revisions were made in the light of the feedback received.

Editorial independence and managing conflict of interests

The production of this Guideline was funded and supported by EAACI. The funder did not have any influence on the guideline production process, on its contents, or on the decision to publish. Taskforce members’ conflict of interests were declared at the start of the process and taken into account by the Taskforce Chairs as recommendations were formulated. Methodologists, who had no conflict of interests in this area, checked final decisions about strength of evidence for recommendations.

Updating the guideline

EAACI plans to update this guideline using the AGREE II approach in 2022 unless there are important advances before then.

AIT for prevention: Evidence and clinical recommendations

Overarching considerations

This Guideline is based on a comprehensive SR evaluating the evidence according to predefined well-established methods [25]. As in other SRs, heterogeneity in the populations under study, methods employed and outcomes studied made it challenging to interpret the evidence. Factors related to the population, such as atopic heredity play a role in the risk of development of allergic disease. In addition, children with sensitization and/or early manifestations of atopic diseases e.g. AD and food allergy or later manifestation such as AR have a higher risk for development of other allergic manifestations such as asthma [17;32]. The age of the population is important as the phenotypic expression may change with age and some manifestations may even disappear spontaneously [33]. The results of individual studies are difficult to compare because studies have used different populations, outcome measures, diagnostic criteria (if any, e.g. the exact definition of asthma,
intermittent versus persistent asthma), methods and cut-off values for measuring sensitization. Furthermore, the mode of administration and the products used for AIT differ as regards allergens, formulation, strength, [34;35] schedules, dose, route of administration and duration of the intervention [36]. Additionally, many studies are small without sufficient power and adjustment for confounders. Where possible, these factors are taken into consideration in the risk of bias assessment in the SR on which this Guideline is based.

The significant heterogeneity seen in meta-analysis can be explained by the study design, study population, products and schedules evaluated. Therefore, an individual product-based evaluation of the evidence for efficacy is strongly recommended before treatment with a specific product is initiated [16;37]. But, caution is recommended as not all AIT products used currently provide sufficient data to support their efficacy in clinical practice. We might consider that a limited class effect can be assumed when the same clinical outcomes were used to evaluate clinical efficacy (and safety) of different products only if the same route of application, similar dosing schemes and demonstrable comparable amounts of relevant allergens and potency were used. However, it should be noted that such comparability is also dependent on standardized and validated assays and that a limited class effect does not neglect the necessity for product specific clinical studies.

Using AIT for prevention of development of new allergic disease or sensitization requires use of products with a high level of safety, especially in healthy individuals. However, if AIT is indicated due to treatment of an already existing allergic disease, and the preventive effect is regarded as an additional effect, then the safety profile should be considered in that context.

Strategies to prevent development of a new sensitization or of a new allergic disease by AIT may vary for different populations at different stages in life. Strategies need to be pursued for different scenarios, e.g. for those planning pregnancy to take measures such as AIT to reduce the likelihood of their child becoming allergic, healthy infants and young children with early manifestations such as AD, older children with manifest allergic disease such as AR, healthy adolescents/adults and adolescents/adults with established allergic disease.
In order to recommend AIT for the prevention of allergic diseases, evidence is required that there is a relevant and substantial beneficial effect on clinical outcomes for the individual. Furthermore, safety aspects of the treatment and of the disease to be avoided, quality of life and evaluation of health economics should be taken into consideration. Thus, an optimal balance between benefits, harms, costs and other possible disadvantages should be achieved (Table 1).

**AIT in individuals with AR: Short- and long-term prevention of development of new asthma**

**Short-term prevention:** The SR [25] identified six RCTs investigating the preventive effect up to two years post-AIT on the development of asthma in individuals with AR. These RCTs included three SCIT studies (one of low [38], one of moderate [39] and one of high risk of bias [40]), one of moderate risk of bias on oral AIT [41] plus one of high [42] and one moderate risk of bias SLIT study [34]. Three of these [38;39;41] were small studies with a trend towards less development of asthma in the AIT group but no significant differences. The remaining three studies [40;42;43] showed a significant reduction of the development of asthma in the AIT groups as compared to the control groups. The SR and meta-analysis [25] demonstrated a significant preventive effect of AIT on the development of asthma up to two years post-AIT in patients with AR. Subgroup analyses showed that AIT with either SLIT or SCIT was beneficial for those aged <18 years but not ≥18 years and for pollen AIT. For HDM AIT the groups were so small that there was a non-statistically significant impact despite an OR of 0.20. There was a high degree of heterogeneity, and therefore the meta-analysis should be interpreted with caution although three RCTs demonstrated a statistically significant preventive effect. Also the results were supported by two large-scale, real-life, retrospective, non-randomized CBAs [44;45], based on German longitudinal prescription databases; both reporting a short-term preventive effect of AIT on the progression from AR to asthma.

**Long-term prevention:** For the long-term preventive effect, i.e. two or more years post-AIT, the SR [25] identified two high risk of bias SCIT RCTs [46;47] in patients with AR. Both showed a significantly lower risk for developing asthma in the SCIT groups as compared to the controls, up to seven years post-AIT [40;46;48], and two years post-AIT [47]. A large recently published low risk of bias RCT (GAP) [49;50] explored the effect of a three-year course of SLIT tablets on the prevention of asthma in 812 children with AR and grass pollen allergy. This study [50] failed to demonstrate the preventive
effect of AIT on the development of asthma as defined by very strict \textit{a priori} criteria including reversibility to beta-2-agonists (OR=0.91; 95\%CI [0.58 to 1.41])\cite{49,50} two years post-AIT. However, the number of subjects with asthma symptoms or asthma medication usage (secondary efficacy parameter) was significantly lower in the SLIT group compared to the placebo group at the end of the five-year trial period (OR 0.66; 95\%CI 0.45 to 0.97; P<0.036), during the two-year post-AIT follow-up and during the entire five-year trial period. Also AR symptoms were significantly reduced during the entire 5 year trial period. In addition, it appeared that this preventive effect was strongest for the youngest children \cite{50}. Two high risk of bias non-randomized studies including one with grass pollen SCIT \cite{22,23} and one with HDM SCIT \cite{51} in children with AR also suggested a long-term effect. As published in the SR \cite{25}, the meta-analysis showed no overall evidence of reduction in the long-term (i.e. at least two years post-AIT) risk of developing asthma, but there was a high degree of heterogeneity so the result should be interpreted with caution. Furthermore, the negative result was due to one RCT with very strict diagnostic criteria for primary outcome (GAP) in which there was an effect when asthma symptoms and/or medication was considered \cite{50}. However, some suggest that there is a long-term preventive effect on the development of asthma symptoms and the use of asthma medication though further confirmatory studies are needed.

Thus, there is a question about which asthma outcome parameter is most relevant – a diagnosis based on demonstrated reversibility or on symptoms and medication use. There is an urgent need to define and standardise the optimal clinical asthma outcomes that should be used in future clinical trials.

\textbf{Indication for AIT for treatment and prevention in patients with AR}

The RCTs included in the above evaluation of asthma prevention in subjects with AR \cite{40,42,43,46,48-50} included patients with a history of AR and the need for medication combined with documented pollen allergy for at least one previous season. Yet, there is no description on AR severity (mild/moderate/severe) or stratification (intermittent/persistent) in these prevention trials, and thus these subjects may have had a milder disease than those included in studies on efficacy of AIT. However, based on baseline descriptions of the populations in these studies \cite{40,42,43,46,48-50}, it is reasonable to assume that most of the patients included had persistent symptoms.
As discussed in another manuscript on AIT for AR of this EAACI AIT Guideline series [10] [52], many patients with AR and pollen allergy benefit from AIT in reducing AR symptoms and need for medication. Thus, AIT is recommended for treatment of patients with moderate-to-severe pollen induced AR if not optimally controlled on antihistamines and nasal corticosteroids [52].

None of the studies on prevention of development of asthma in AR included preschool children and therefore no recommendations can currently be made in favor of or against AIT for this age group for prevention.

Based on an objective and clinical evaluation of the current published evidence for AIT preventive effects and considering the potential harmful effects, disadvantages and costs associated with the use of AIT, these seem to be outweighed by the beneficial effects for this group of patients (Table 1) ultimately resulting in a favorable risk benefit profile.

Thus, there is moderate-to-high quality evidence indicating that AIT (SCIT or SLIT) can be recommended for short-term prevention up to two years post-AIT of asthma in children/adolescents with moderate/severe AR and pollen allergy who are sub-optimally controlled despite appropriate pharmacotherapy, and there are data suggesting that this benefit persists after two years post-AIT as regards asthma symptoms and medication use (Table 3). AIT may even be considered in patients with milder AR, as AIT might modify the natural disease history, including the long-term effect in AR and the preventive effect regarding the development of asthma, qualities which could never be attributed to current pharmacotherapy.

The indication and initiation of AIT should always be preceded by a discussion with the patient / family considering the possible benefits, harms, disadvantages, costs, preferential route of AIT (SCIT vs SLIT) based on the individual patient's profile, preferences and considerations for future AIT adherence. Using AIT for preventive purposes should include all normal safety recommendations as for treatment of AR as indicated in the corresponding Guideline on AIT for AR in this EAACI AIT Guideline series [52].
Which products and schedules for AIT asthma prevention in individuals with AR should be used?

The products, doses and AIT schedules used in the AIT prevention trials vary. According to the subgroup analysis in the SR [25] it appears that SCIT and SLIT are both effective, and that a three-year AIT course is preferable to a shorter course. The studies that have demonstrated a preventive effect used three-year courses of continuous AIT.

The SR [25] did not compare different AIT products, SLIT drops versus tablets or pre/co-seasonal versus perennial AIT. However, according to the results from two lower quality, real-life non-randomized, controlled before-after AIT treatment studies based on large German longitudinal prescription databases [44;45], it seems that SCIT [45] and grass pollen SLIT tablets [44] with natural allergen extracts have a preventive effect on the progression from AR to asthma, and that AIT for three or more years tended to have a stronger preventive effect than AIT for less than three years. Further high-quality RCTs and real-life studies are recommended to objectively confirm this.

Since the indication for AIT for prevention of asthma is linked to the indication for treatment of AR, the products, schedules and doses used should be proven effective for AR with the relevant allergen product. Therefore, only those products registered and with the indication for AR (e.g. pollen allergy at present and maybe HDM in the future) should be considered for use in allergy prevention.

AIT in individuals with AD: Short- and long-term preventive effects

The SR [25] identified one moderate risk of bias RCT investigating the effects of 12 months of daily SLIT with a mixture of HDM, cat and Timothy grass allergens on the prevention of asthma and new sensitizations in children with AD and sensitization to one or more food allergens [53]. The investigators included the absence of a difference between active/placebo groups in early immunological changes, i.e. specific IgE/IgG antibodies and associated T\textsubscript{H}-cell responses, as a stopping rule, since this was regarded an indication of whether the treatment was delivering sufficient allergen transmucosally to trigger immunological recognition by the infant mucosal system. As these \textit{a priori} immunological changes were not met, recruitment was interrupted and the trial reduced to a pilot study status. After 48 months of follow-up, there were no differences in asthma prevalence between the two groups [53].
Based on this study, we cannot currently make any recommendations in favour of or against AIT for the prevention of the development of a first allergic disease in individuals with AD at present (Table 4) and more studies are needed.

**AIT for prevention of allergy in the offspring of allergic individuals**

This topic was not included in the protocol or in the SR. However, we found one recent case-control study of high risk of bias comparing 194 children of parents completing AIT at least nine months before birth with 195 controls [54]. This study found that the odds ratios of developing any allergic disease and asthma was significantly lower in children with at least one allergic parent after AIT compared with those having allergic parents who did not receive AIT (odds ratio: 0.73, 95% confidence interval 0.59-0.86). The authors hypothesized that AIT in allergic parents might reduce the risk of allergies in their offspring, but this requires further investigation.

Based on the very scarce and very low quality evidence, we cannot currently make any recommendations in favour of or against AIT for allergic adults for prevention of allergic disease in their offspring (Table 5).

**AIT in healthy individuals: Short- and long-term prevention of development of new allergic disease**

Two RCTs, one of low [55] and one of high risk of bias [56], investigated the possible effect of AIT in healthy individuals on the risk for development of their first allergic disease. The large low risk of bias study [55] found no preventive effect of oral HDM AIT on AD, wheeze and food allergy among infants with a family history of allergic diseases, whereas the small high risk of bias study [56] reported a reduced risk of developing pollinosis among asymptomatic adults sensitized to Japanese cedar pollen in the SLIT group. Data from these two trials [55;56] are not comparable. No data on a long-term preventive effect were identified. Based on these results from the SR [25] there is currently no good evidence to recommend use of AIT for the prevention of a first allergic disease in healthy individuals (Table 5)
**AIT for the prevention of the development of new allergic sensitization**

**Short-term effects:** The SR identified three low risk of bias RCTs [55;57;58], one moderate [59] and two high risk of bias [42;60] RCTs investigating the short-term effects of AIT on the risk of developing new sensitizations. One low risk of bias RCT [55] on oral HDM AIT for healthy infants at high risk of developing allergic disease found a significant reduction in sensitization to any common allergen (e.g. HDM, grass pollen, cat, peanut, milk and egg) in the active group compared with the placebo group at the end of the trial, but no difference in HDM sensitization [55]. The other two low risk of bias RCTs found no effect of SLIT in adult patients allergic to peach [57] post-AIT and after SLIT with grass pollen or HDM extract in mono-sensitized children [58]. Three additional RCTs of moderate to high risk of bias [42;59;60] found a significantly lower incidence of new sensitizations among children and adults with AR treated with SLIT [42;60] and SCIT [59] as compared to controls.

Thus, these RCTs of varying quality with varying allergens and formulations showed inconsistent results. Meta-analysis showed an overall reduction in the risk of allergic sensitization but the sensitivity analyses, excluding the two high risk of bias studies by Marogna [42;60], failed to confirm this risk reduction [25]. Due to the high degree of heterogeneity, the results from the meta-analysis should be interpreted with caution.

The inconsistent evidence found in RCTs was also reflected in the included high risk of bias CBA studies with three finding a lower occurrence of new sensitizations among AIT treated subjects compared with controls [61-63], one reporting higher occurrence in the AIT group compared with controls [64] and three studies reporting no differences between groups [65;66;67].

**Long-term effects:** As regards the long-term (i.e. at least two years post-AIT) effects on prevention of new sensitivities the SR identified one moderate [68] and one high risk of bias RCT [69] showing no preventive effect of SCIT among children with moderate-to-severe asthma followed into adulthood [68] and SCIT in adults with AR three years post-AIT [69]. Another high risk of bias RCT [47] found that patients with AR treated with HDM SCIT less frequently developed new sensitizations compared with controls two years post-AIT [47].
Thus, there is no good evidence for a reduction in the long-term risk of allergic sensitization.

The seven high risk of bias CBAs investigating long-term preventive effects of AIT produced inconsistent results, one found no difference [70], four showed reduced onset [22;62;71-73] and one found a significantly higher occurrence of new sensitization among AIT treated compared with controls [74].

The development of new sensitizations may impose a higher risk for the development of further symptomatic allergies suggesting that it might be relevant to prevent the development of new sensitizations. However, this has not been investigated sufficiently. A subgroup analysis in the SR [25] showed a tendency towards an effect in children and adolescents after three years of AIT, supporting the rationale of the clinical effect.

Thus, there is currently no good evidence to recommend the use of AIT for either short- or long-term prevention of development of new sensitizations in healthy individuals, children with atopic predisposition (Table 5), children with AD / food allergy (Table 4) or in children and adults with AR / asthma (Table 3). Some positive data though suggests that this may be a good focus for future high quality trials.
<table>
<thead>
<tr>
<th>Population</th>
<th>Benefits</th>
<th>Harms / disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy +/- sensitization</td>
<td>Possible preventive effect</td>
<td>Daily intake of tablets/drops (SLIT/oral) or regular injections (SCIT) for 3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Frequency of visits to the clinic (SCIT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Risk for adverse events</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Costs*</td>
</tr>
<tr>
<td>Children with AD</td>
<td>Possible preventive effect not documented</td>
<td>Daily intake of tablets/drops (SLIT/oral) or regular injections (SCIT) for 3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Frequency of visits to the clinic (SCIT)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Risk of adverse events</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Costs*</td>
</tr>
<tr>
<td>Patients with AR</td>
<td>Documented beneficial effect on symptoms and reduction in medication on</td>
<td>Daily intake of tablets/drops (SLIT/oral) or regular injections (SCIT) for 3 years</td>
</tr>
<tr>
<td></td>
<td>short - and long-term</td>
<td>Frequency of visits to the clinic (SCIT)</td>
</tr>
<tr>
<td></td>
<td>Possible preventive effect on development of asthma</td>
<td>Risk for adverse events</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Costs*</td>
</tr>
</tbody>
</table>

* Costs should be evaluated in relation to potential direct and indirect costs related to the development of an eventual allergic disease and other comorbidities

AIT: Allergen immunotherapy; AD: Atopic dermatitis / eczema; AR: Allergic rhinitis / rhinoconjunctivitis
### Table 2. Gaps in the evidence

<table>
<thead>
<tr>
<th>Gaps</th>
<th>Plan to address</th>
<th>Priority</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIT for prevention of asthma in children with AR due to grass pollen - long term effects</td>
<td>Long-term follow up of RCTs Further evaluation of GAP trial</td>
<td>High</td>
</tr>
<tr>
<td>AIT for prevention of asthma in children with AR due to HDM</td>
<td>RCTs*</td>
<td>High</td>
</tr>
<tr>
<td>Optimal age for introduction of AIT for prevention</td>
<td>RCTs*</td>
<td>High</td>
</tr>
<tr>
<td>Optimal duration of AIT for prevention</td>
<td>RCTs*</td>
<td>High</td>
</tr>
<tr>
<td>Optimal product, administration form, dose and schedule of AIT for prevention</td>
<td>RCTs* and high quality real life studies</td>
<td>High</td>
</tr>
<tr>
<td>Evaluation of influence of AIT for prevention on QoL in different age groups</td>
<td>QoL as outcome in RCTs*</td>
<td>High</td>
</tr>
<tr>
<td>AIT for prevention of AR / asthma in children and adults with AD / food allergy</td>
<td>RCTs*</td>
<td>Medium</td>
</tr>
<tr>
<td>Evaluation of health economics of AIT for prevention</td>
<td>Cost-effectiveness analysis of RCT</td>
<td>Medium</td>
</tr>
<tr>
<td>Evaluation of adherence in AIT for prevention in different age groups</td>
<td>Adherence measured in RCTs and real life studies</td>
<td>Medium</td>
</tr>
<tr>
<td>Evaluation of acceptability of AIT for prevention in different age groups</td>
<td>RCTs*</td>
<td>Medium</td>
</tr>
<tr>
<td>AIT for the prevention of new allergic sensitizations</td>
<td>RCTs*</td>
<td>Medium</td>
</tr>
<tr>
<td>- spreading from one allergen to related and unrelated allergen(s)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- spreading at molecular level, from one allergenic molecule to other molecules</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AIT for prevention of the Oral Allergy Syndrome</td>
<td>RCTs*</td>
<td>Low</td>
</tr>
<tr>
<td>AIT for prevention of first allergic disease</td>
<td>RCTs*</td>
<td>Low</td>
</tr>
</tbody>
</table>

*Apart from new RCTs, published clinical data can be reviewed, raw data can be reanalyzed and blood samples can be analyzed further to provide new data.*

AIT: Allergen immunotherapy; AD: Atopic dermatitis / eczema; AR: Allergic rhinitis / rhinoconjunctivitis; HDM: house dust mites
<table>
<thead>
<tr>
<th>Recommendations for individuals with manifest allergic disease(s), e.g. allergic rhinitis</th>
<th>Evidence level</th>
<th>Grade of recommendation</th>
<th>Strength of recommendation</th>
<th>Other considerations</th>
<th>Key references</th>
</tr>
</thead>
<tbody>
<tr>
<td>In children and adolescents with AR and grass/birch pollen allergy, who are sub-optimally controlled despite appropriate treatment with antihistamines / nasal corticosteroids, a 3 year course of AIT (SCIT or SLIT) can be recommended for the short-term (i.e. &lt; 2 years post AIT) prevention of the onset of asthma in addition to the sustained effect on AR symptoms and medication use.</td>
<td>I</td>
<td>A</td>
<td>Moderate recommendation: Based on consistent significant results from 2 moderate [41;43] and 2 high risk of bias [40;42] RCTs and some CBA studies</td>
<td>The indication should be discussed with the patients / families including the asthma preventive effect as well as the effect on AR and risk of adverse effects, costs and preferences</td>
<td>Möller1986 [41], Möller2002 [40], Novembre 2004 [43], Marogna 2008 [42], Kristiansen 2017 [25]</td>
</tr>
<tr>
<td>In children and adolescents with AR and grass/birch pollen allergy, no recommendation can currently be made in favor of or against the use of AIT (SCIT or SLIT) for the long-term (≥ 2 years post AIT) prevention of the onset of asthma as diagnosed by symptoms combined with demonstrated reversibility</td>
<td>I</td>
<td>B</td>
<td>Weak recommendation: Based on consistent results from 2 high risk of bias RCTs [46] [47], non-significant results from low risk of bias RCT [50], and the meta-analyses being not significant due to the latter study</td>
<td>In the Valovirta 2017 [50] study no effect on the primary asthma outcome using a restrictive definition of asthma based on demonstration of reversibility. More data is needed</td>
<td>Jacobsen 2007 [46], Song 2014 [47], Valovirta 2017 [50], Kristiansen 2017 [25]</td>
</tr>
<tr>
<td>In children and adolescents with AR and allergy to house dust mites or other allergens except for birch/grass pollen, no recommendation can currently be made in favor of or against the use of AIT (SCIT or SLIT) for the short-term (i.e. &lt; 2 years post AIT) or long-term (i.e. ≥ 2 years post AIT) prevention of the</td>
<td>I</td>
<td>B</td>
<td>Weak -moderate recommendation: Based on consistent results from 2 high risk of bias RCTs [46] [47] and secondary outcomes in 1 low risk of bias RCT [50].</td>
<td>In the Valovirta 2017 [50] study a significant preventive effect on the secondary outcomes asthma symptoms and medication was found. More data is needed</td>
<td>Jacobsen 2007 [46], Song 2014 [47], Valovirta 2017 [50], Kristiansen 2017 [25]</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Only HDM, parietaria and mix of these and grass/birch pollen investigated. More data is needed</td>
<td>Marogna 2008 [42], Crimi 2004 [39], Grembiale 2000 [38], Kristiansen 2017[25]</td>
</tr>
<tr>
<td>Onset of Asthma</td>
<td>Grade</td>
<td>Quality</td>
<td>Recommendation</td>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------------</td>
<td>-------</td>
<td>---------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>In adults with AR and house dust mite or pollen allergy, no recommendation can currently be made in favor of or against the use of AIT (SCIT or SLIT) for the short-term (i.e. &lt; 2 years post AIT) or long-term (i.e. ≥ 2 years post AIT) prevention of the onset of asthma</td>
<td>I</td>
<td>B</td>
<td>Weak recommendation: Based on 1 small moderate risk of bias study [39]</td>
<td>Only SCIT with Parietaria Judaica investigated. More data is needed</td>
<td></td>
</tr>
<tr>
<td>In children or adults with AR and/or asthma, AIT cannot currently be recommended for the prevention of new sensitizations,</td>
<td>I</td>
<td>B</td>
<td>Weak recommendation: Based on inconsistent results from 4 high [42;47;60;69], 2 moderate [59;68] and 3 low risk of bias [55;57;58] RCTs</td>
<td>Marogna 2004 [60], Marogna 2008 [42], Dominicus 2012 [69], Song 2016 [47], Pifferi 2002 [59], Limb 2006 [68], Garcia 2010 [57], Szepfalusi 2014 [58], Zolkipli 2015 [55], Kristiansen 2017 [25]</td>
<td></td>
</tr>
</tbody>
</table>
Table 4. AIT for prevention: recommendations for individuals with early life atopic manifestations, e.g. atopic dermatitis/eczema (AD) or food allergy

<table>
<thead>
<tr>
<th>Recommendations for individuals with early atopic manifestations</th>
<th>Evidence level</th>
<th>Grade of recommendation</th>
<th>Strength of recommendation</th>
<th>Other considerations</th>
<th>Key references</th>
</tr>
</thead>
<tbody>
<tr>
<td>In children with AD, AIT no recommendations can currently be made in favor of or against the use of AIT for the prevention of onset of later allergic manifestations</td>
<td>I</td>
<td>B</td>
<td>Weak recommendation: Based on 1 small moderate risk of bias study [53]</td>
<td></td>
<td>Holt 2013 [53]</td>
</tr>
<tr>
<td>In individuals at all ages with other early atopic manifestations e.g. food allergy, no recommendations can currently be made in favor of or against the use of AIT for the prevention of onset of other allergic manifestations</td>
<td>V</td>
<td>D</td>
<td>Expert opinion. No studies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 5. AIT for prevention: recommendations for healthy individuals

<table>
<thead>
<tr>
<th>Recommendations for healthy individuals all ages</th>
<th>Evidence level</th>
<th>Grade of recommendation</th>
<th>Strength of recommendation</th>
<th>Other considerations</th>
<th>Key references</th>
</tr>
</thead>
<tbody>
<tr>
<td>In adult allergic patients, no recommendations can currently be made in favor of or against the use of AIT for the prevention of onset of allergic diseases in their offspring</td>
<td>IV-V</td>
<td>D</td>
<td>Weak recommendation: Based on results from 1 high risk of bias study [54]</td>
<td></td>
<td>Bozek, 2016 [54]</td>
</tr>
<tr>
<td>In healthy individuals with or without sensitization, AIT cannot currently be recommended for prevention of onset of allergic diseases</td>
<td>I</td>
<td>A</td>
<td>Weak recommendation: Based on 1 low [55] and 1 high risk of bias RCTs [56]</td>
<td>One RCT with infant and one with adult population</td>
<td>Zolkipli 2015 [55], Yamanaka 2015 [56]</td>
</tr>
<tr>
<td>In healthy children, AIT cannot currently be recommended for the prevention of new sensitizations</td>
<td>I</td>
<td>B</td>
<td>Weak to moderate recommendation: Based on results from 2 low risk of bias RCTs [55] [58]</td>
<td>One RCT with infant and one with preschool population</td>
<td>Zolkipli 2015 [55], Szepfalusi 2014 [58]</td>
</tr>
<tr>
<td>In healthy adults, no recommendations can currently be made in favor of or against the use of AIT for the prevention of new sensitizations</td>
<td>V</td>
<td>D</td>
<td>Expert opinion. No studies</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Table 6: Recommendations for individuals with allergic rhinitis: Implementation

<table>
<thead>
<tr>
<th>Prevention of development of asthma in patients with AR</th>
<th>Barriers to implementation</th>
<th>Facilitators to implementation</th>
<th>Audit criteria</th>
<th>Resource implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>In children and adolescents with AR and grass/birch pollen allergy who are sub-optimally controlled despite appropriate treatment with antihistamines / nasal corticosteroids, a 3 year course of AIT (SCIT or SLIT) can be recommended for short-term (i.e. &lt; 2 years post AIT) prevention of the onset of asthma in children with daily symptoms and need for medication</td>
<td>Lack of recognized policy in Europe about allergies and their treatment.</td>
<td>Government and European policy on allergy.</td>
<td>Proportion of potentially eligible patients referred from primary care for a specialist assessment</td>
<td>Identification of patients who may benefit from AIT. Thorough investigation of the patient including proper assessment of relevant allergies.</td>
</tr>
<tr>
<td></td>
<td>Failure to recognize manifestations in primary care.</td>
<td>Reimbursement of AIT</td>
<td>Proportion of potentially eligible patients formally considered for AIT</td>
<td>AIT need to be prescribed, made available and administered to patients.</td>
</tr>
<tr>
<td></td>
<td>Lack of knowledge amongst patients, caregivers and primary care professionals about the benefits of AIT.</td>
<td>Accessible education and training in allergy primary care.</td>
<td></td>
<td>Evaluation of effect and eventual AEs</td>
</tr>
<tr>
<td></td>
<td>Lack of communication specialists / primary care interface or specific referral criteria primary care.</td>
<td>Agreed competencies in allergy for primary care and allied health workers for shared care protocols.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lack of agreed clinical pathways</td>
<td>Information amongst patients, caregivers and healthcare professionals about the benefits of AIT.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lack of access to AIT</td>
<td>Integrated multidisciplinary working and service delivery.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unavailability of AIT</td>
<td>Timely advice and continuous guidance by specialists.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>No reimbursement</td>
<td>Workforce remodeling.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Costs of travel and time of work for patients and caregivers</td>
<td>Agreed pathways of care with cross boundary working</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Concerns about side-effects and safety of especially SCIT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lack of health economics data</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

This article is protected by copyright. All rights reserved.
Safety

The safety issues are fully covered by the SR and guideline for AR in this AIT guideline series [10;52]. SCIT is occasionally associated with allergic side effects and should therefore be administered in a specialist setting. Fatalities are very rare and have not been reported with the use of SLIT. In a recent meta-analysis about the efficacy of grass-pollen SLIT tablet by Di Bona et al. [75] seven treatment related adverse events requiring adrenaline were reported in the SLIT RCTs, however no episode of anaphylaxis was reported. In recent real-life clinical studies of AIT, less severe systemic reactions were reported with SLIT than with SCIT, although the overall rate of adverse reactions is similar in SCIT and SCIT [76;77]. The safety profile for the present purpose is not regarded as being different from AIT for treatment of AR. Due to its better safety profile SLIT might be a better choice for prevention than SCIT.

Summary, gaps in the evidence, future perspectives and implementation

This Guideline on AIT for prevention of allergy has been developed as part of the EAACI Guidelines on Allergen Immunotherapy project. The recommendations in this Guideline are based on a thorough SR performed by a group of experienced and independent methodologists and have been developed by a multidisciplinary EAACI Task Force representing a range of countries and disciplines and clinical backgrounds.

The Guideline provides evidence-based recommendations for the use of AIT for prevention of new allergic disease(s) and new allergic sensitization(s) in all populations. The guideline should assist all healthcare professionals as regards evaluation of AIT for prevention of allergic disease /sensitization, and when to refer which individuals to further evaluation. The main results are summarized in Box 4.

The key limitation of this guideline is the heterogeneity and gaps in the underpinning literature. There are many areas for which there is no evidence or no high quality evidence; these represent gaps in the current evidence (Table 2). Thus, for the preventive effect of AIT in healthy individuals or in children with early atopic manifestations such as AD or food allergy as well as for the possible long-term effect in children with AR, more high quality data are needed. Also, we did not find studies related to spreading of allergic sensitization(s) at the molecular level, nor did we identify studies exploring the development of new OAS or health economic analyses of AIT used for prevention.
In addition, there is a lack of evidence as regards patient selection (e.g. optimal age and characteristics) for preventive AIT and for the optimal allergen preparation, mode and duration of AIT administration; there is a need to define standardized relevant outcomes including asthma and quality of life (QoL) for future studies.

The current evidence does not allow to identify superiority between SCIT and SLIT; therefore, this choice depends on availability, patients’ family’s preferences, safety, costs, routes, schedules and patients adherence to the AIT treatment. Only products and regimens proven effective for treatment of AR should be used. Currently only products with the indication for treatment of AR can be recommended for prevention of asthma in children and adolescents with AR and pollen allergy.

Based on current evidence, AIT can be recommended for up to two years post-AIT of development of asthma in children and adolescents with AR and pollen allergy primarily birch and grass. Some studies suggest a long-term asthma preventive effect as regards asthma symptoms and medication use, though it has to be further demonstrated if this effect can be extended to asthma as diagnosed by stricter diagnostic criteria. Such a disease-modifying effect after cessation of AIT is not achievable with pharmacotherapy. AIT should in particular be considered for those with moderate-severe AR as it has been shown to be effective in controlling this condition in addition to the preventive effect on the development of asthma [10;52]. Furthermore, some patients with less severe AR may prefer AIT to reduce medication use and avoid side effects of other treatments, to obtain long-term efficacy and/or to obtain the asthma preventive effect.

Considerations should be taken when making recommendations for AIT as preventive treatment in allergy, as children and adolescents included in the prevention studies did not necessarily fulfill the criteria for proper endorsement of AIT for treatment of AR as well as they did not necessarily meet the “Allergic Rhinitis and its Impact on Asthma” (ARIA)[9] criteria for moderate/severe AR.

At present, the indications for AIT for prevention of allergic disease are the same as for treatment of AR (i.e. documented IgE-mediated disease caused by the relevant allergens and not sufficiently controlled by antihistamines and nasal corticosteroids) [52]. Contraindications are the same as for treatment of AR [52]. The asthma preventive effect may in the future downgrade the level of severity of AR required before initiation of AIT in children and adolescents with AR and pollen allergy, especially grass pollen allergy. Therefore, AIT as a relevant treatment option for children and
adolescents up to 18 years of age with less severe AR due to pollen allergy should be further investigated and discussed. Currently, there is no high quality evidence to support AIT for prevention in HDM allergic patients with AR, but further high quality studies are warranted.

The products available, and registered for different indications, have varied over time and across countries. Therefore, at present we cannot make homogeneous product specific recommendations at a European level. In the context of the implementation of this guideline series, we plan to provide such recommendations based on the on each national country availability of the products

For the implementation of this Guideline (described in Table 6) there is a need to ensure that primary care healthcare professionals recognise AIT as a treatment option for some allergic diseases and have clear guidelines to aid patient selection for early referral to specialist care [78]. Patients and patient organizations need to be aware of AIT as a treatment option. Political awareness should be increased to ensure sufficient availability, knowledge, competences, skills and resources in the health care system by demonstrating the economic benefits of AIT by proper assessment of its positive impact on economic productivity. In addition, methods to overcome problems with adherence should be further considered and evaluated. Finally, a plan for monitoring the audit criteria should be part of the dissemination and implementation plan, and as new evidence is published these guidelines will be updated with appropriate revision of specific recommendations.
**Box 4 Summary**

- A three year course of AIT (SCIT or SLIT) can be considered in children with moderate to severe AR and grass/birch pollen allergy, not sufficiently controlled with optimal pharmacotherapy, for
  - Treatment of AR with a sustained effect on symptoms and use of medication beyond cessation of AIT
  - Short-term (i.e. up to 2 years post-treatment) prevention of the onset of asthma in addition to improving the control of AR. Moreover, some studies indicate that this asthma preventive effect is maintained over a longer period as evaluated by symptoms and medication use.
- Only AIT products with documented effect in patients with the relevant pollen allergy should be used and a product specific evaluation of clinical efficacy and preventive effects is recommended
- Before initiating AIT the possible benefits including the beneficial effects on controlling AR symptoms, disadvantages, potential harms, patients’ preferences (SCIT or SLIT-tablets/SLIT-drops), patients’ adherence to treatment and costs should be discussed with the patient / family on an individual basis
- There is an urgent need for more high-quality clinical trials on prevention in AIT and more high quality evidence.
Box 5 Key messages for primary care about referral to allergy services

- AIT have a role in delaying/preventing progression from seasonal AR/ARC to asthma
  - Primary care teams should consider early referral of children with troublesome AR in spite of pharmacotherapy with antihistamine and or nasal corticosteroids for a specialist assessment with a view to considering AIT to improve control of AR and also simultaneously delay/prevent asthma
  - Patients should be considered as “individuals” during the assessment to prescribe AIT, they all have to be aware of the potential benefits, risks and costs of AIT
- AIT may be indicated in those individuals with perennial AR on clinical grounds but not only for delaying/preventing progression to asthma (this preventive effect needs to have high quality evidence)
- Recommendations cannot currently be made for AIT to prevent: (i) allergic parents who would be interested in receiving AIT to prevent allergy in their offspring; (ii) healthy infants/children; (iii) infants/children with AD and/or food allergy

Acknowledgements

We would like to acknowledge the support of EAACI and the EAACI Guidelines on Allergen Immunotherapy Group in developing this guideline. We would like to thank Kate Crowley for her assistance in preparing the guidelines; thank Stefan Vieths, Andreas Bonertz and Sergio Bonini for their advice; Stephen Durham, Peter Eng, Hans Jørgen Malling, Antonio Nieto, Zsolt Szepfalusi and Erkka Valovirta for their expert review of the draft guidelines; all the EAACI members who commented about the draft guideline on the public website; EAACI and the “BM4SIT project (grant number 601763) in the European Union's Seventh Framework Programme FP7” for funding this guideline.

Authors’ contribution

S Halken chaired the EAACI Guideline AIT for Allergy Prevention Taskforce. D Larenas-Linnemann, G Roberts, MA Calderón, M Penagos, S Bonini, G Du Toit, IJ Ansotegui, J Kleine-Tebbe, S Lau, P Maria Matricardi, G Pajno, NG Papadopoulos, O Pfaar, D Ryan, AF Santos, F Timmermans, U Wahn, M Kristiansen, S Dhami, A Sheikh and A Muraro were all members of the Taskforce and were involved in conceptualizing the guideline, drafting of the guideline and critically reviewed the guidelines draft and I Agache, S Arasi, M Fernandez-Rivas, M Jutel, GJ Sturm, EM Varga, R van Ree,
R Gerth van Wijk, and Antonella Muraro were members of the Chairs Steering group who also critically discussed and reviewed the guideline draft. F Timmermans was also the patient group representative. All the authors satisfied the international Vancouver authorship criteria. This guideline is part of the EAACI Guidelines on Allergen Immunotherapy, chaired by Antonella Muraro and coordinated by Graham Roberts. All authors’ job titles and role in the guideline development is in Table E1 in the online repository.

Conflicts of interest

S. Halken reports personal fees from ALK-Abelló, personal fees from Different companies e.g. MEDA, Stallergenes, Allergopharma and ALK-Abelló, outside the submitted work;

D. Larenas-Linnemann reports personal fees from MSD, Grunenthal, Amstrong and DBV; grants and personal fees from Astrazeneca, MEDA, GSK, Pfizer, Novartis, Boehringer-ingelheim, Sanofi, UCB; grants from Chiesi and TEVA; other from Stallergenes and from ALK-Abelló, outside the submitted work; she is the Chair of the immunotherapy committee CMICA, member of the immunotherapy committee or interest groups of EAACI, WAO, SLAAI and member and Program Chair of the Board of Directors CMICA 2018-2019;

G. Roberts has a patent issued: “Use of sublingual immunotherapy to prevent the development of allergy in at risk infants”; and his university has received payments for the activities he has undertaken giving expert advice to ALK, and presenting at company symposia for ALK, Allergen Therapeutics, and Meda, and serving as a member of an Independent Data Monitoring Committee for Merck outside of this work;

M. A. Calderón has received honorarium in advisory boards for ALK and Hal-Allergy and served as a speaker for ALK, Merck, Hal-Allergy, Allergopharma and Stallergenes Greer;

E. Angier reports being Secretary of Primary Care Interest Group EAACI. ALK conference SOSA meeting 2015. Previous paid advisory board one each for MEDA 2012, Stallergenes, 2012, Schering Plough 2009 and one paid lecture by MEDA;

I. Agache has nothing to disclose;

I. J. Ansotegui has nothing to disclose;

S. Arasi has nothing to disclose;

This article is protected by copyright. All rights reserved.
George Du Toit reports income from grants from National Institute of Allergy and Infectious Diseases (NIAID, NIH), Food Allergy & Research Education (FARE), MRC & Asthma UK Centre, UK Dept of Health through NIHR, National Peanut Board (NPB), and grants from UK Food Standards Agency (FSA); these grants part funded salary. Prof. Du Toit is; scientific advisor for the Anaphylaxis Campaign, advisor to - and holds stock in - FoodMaestro and is site investigator for Aimmune-sponsored Peanut Desensitisation Trials and is Scientific advisor to Aimmune. He was Chairperson of the EAACI Paediatric Section over the period when this document was formulated;

Montserrat Fernandez-Rivas reports grants from European Union, grants from Instituto de Salud Carlos III, Ministerio de Ciencia, España, grants from Ministerio de Economía, España, personal fees from DBV, personal fees from Aimmune, Reacta Biotech, Schreiber foods, personal fees from ALK Abello, Merck, GSK, Allergy Therapeutics, non-financial support from EAACI, personal fees and non-financial support from Fundación SEAIC, other from Hospital Clínico San Carlos, and Universidad Complutense de Madrid, España, outside the submitted work; In addition, Dr. Fernandez Rivas has a patent PT0042/2013 issued;

R. Gerth van Wijk reports personal fees from ALK-Abello, Circassia, and Allergopharma, during the conduct of this work;

M. Jutel reports personal fees from Allergopharma, Anergis, Stallergen, ALK and Leti outside the submitted work;

J. Kleine-Tebbe reports personal fees for 1. Advisory Board membership (ALK-Abelló, Bencard, Leti, Novartis), personal fees for 2. Consultancy (Circassia, UK; MERCK, US), institutional grants from 3. Circassia, UK, LETI, Lofarma, Stallergenes, personal fees from for 4. Lectures including service on speakers bureaus (Allergopharma, Allergy Therapeutics, ALK-Abelló, AstraZeneca, Bencard, HAL Allergy, LETI, Lofarma, Novartis, Sanofi, Stallergenes Greer, ThermoFisher) outside the submitted work;

S. Lau reports grants from Allergopharma, personal fees from Merck, during the conduct of the study; grants from Symbiopharm Herborn, grants from Boehringer, outside the submitted work;

P.M. Matricardi has nothing to disclose;

G. Pajno reports grants from Stallergenes during the conduct of this work;
N.G. Papadopoulos reports grants from Menarini, personal fees from Novartis, personal fees from Faes Farma, personal fees from BIOMAY, personal fees from HAL, personal fees from Nutricia Research, personal fees from Menarini, personal fees from Novartis, personal fees from MEDA, personal fees from Abbvie, personal fees from Novartis, personal fees from MEDA, personal fees from MSD, personal fees from MEDA, personal fees from Omega Pharma, personal fees from Danone, outside the submitted work;

M. Penagos reports personal fees from Stallergenes and ALK, outside this work;

O. Pfaar reports grants and personal fees from ALK-Abello, Allergopharma, Stallergenes Greer, HAL-Allergy Holding B.V./HAL-Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biotech Tools S.A., Laboratorios LETI/LETI Pharma, and Anergis S.A.; grants from Biomay, Nuvo, and Circassia; and personal fees from MEDA Pharma, Sanofi US Services, Mobile Chamber Experts (a GA²LEN Partner), Novartis Pharma and PohlBoskamp, outside this work;

D. Ryan reports personal fees from MEDA, personal fees from Stallergenes, personal fees from Thermo Fisher, from null, outside the submitted work; and 1. Consultantt Strategic Clinical Advisor, Optimum Patient Care. Director, Respiratory Effectiveness Group. Chair, Primary Care Interest Group, EAACI;

A.F. Santos reports grants from Medical Research Council, grants from Immune Tolerance Network/NIAID, personal fees and other from Thermo Fisher Scientific, Nutricia, Infomed, outside the submitted work;

G.J. Sturm reports grants from ALK Abello, personal fees from Novartis, personal fees from Bencard, personal fees from Stallergens, outside the submitted work;

F. Timmermans has nothing to disclose;

R. van Ree: Consultancy and speaker fees for HAL Allergy BV, consultancy for Citeq BV and speaker fees for ThermoFisher Scientific. Funding from EU FP7, Dutch Science Foundation and HESI-ILSI.

E-M Varga reports lecture fees from ALK-Abello, Stallergenes-Greer, Allergopharma, Bencard, MEDA and Nutricia outside the submitted work;

U. Wahn reports personal fees from Allergopharma, personal fees from ALK-Abello, personal fees from Stallergenes-Greer, personal fees from Biomay, outside the submitted work;

This article is protected by copyright. All rights reserved.
M. Kristiansen has nothing to disclose;

S. Dhami reports grants from EAACI to carry out the review, during the conduct of this work;

A. Sheikh reports grants from the EAACI during the conduct of this work;

A. Muraro reports consultant fees from Meda-Mylan, other from Stallergenes-Greer, other from ALK, other from Nestlé, outside the submitted work.

References


16. Pfaar O, Bachert C, Bufl A, Buhl R, Ebner C, Eng P, Friedrichs F, Fuchs T, Hamelmann E, Hartwig-Bade D, Herit J, Huttegger I, Jung K, Klimek L, Kopp MV, Merk H, Rabe U, Saloga J, Schmid-Grendelmeier P, Schuster A, Schwark N, Sitter H, Umpfenbach U, Wedi B, Wohrl S, Worm M, Kleine-Tebbe J, Kaul S, Schwalfenberg A. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Otorhinolaryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German
Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD). Allergo J Int 2014; 23:282-319.


This article is protected by copyright. All rights reserved.


31. Oxford Centre for Evidence-based medicine. Levels of Evidence and Grades of Recommendation. 2013. 31-3-2013. Ref Type: Online Source


This article is protected by copyright. All rights reserved.


47. Song W, Lin X, Chai R. [Efficacy evaluation of standardized dust mite allergen specific immunotherapy to patients of allergic rhinitis]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2014; 28:300-2.


64. Asero R. Injection immunotherapy with different airborne allergens did not prevent de novo sensitization to ragweed and birch pollen north of Milan. Int Arch Allergy Immunol 2004; 133:49-54.


This article is protected by copyright. All rights reserved.


This article is protected by copyright. All rights reserved.